GlaxoSmithKline receives European Commission approval to market alli® (orlistat 60mg)

CU Anschutz Clinical Trial Tests Orforglipron, an Oral GLP-1 Pill as Alternative to Injectable Weight-Loss Drugs

Orforglipron is an FDA-approved non-peptide oral GLP-1 pill being studied as an alternative to injectable weight-loss drugs like Ozempic and

GLP-1-boosting fibre approved as safe by European regulator, could be added to foods within a year

A novel form of fibre that stimulates the release of hunger-reducing hormones like GLP-1 (similar to drugs such as Wegovy and Ozempic) has b

GLP-1-boosting fibre approved as safe by European regulator, could be added to foods within a year

A novel form of fibre that stimulates the release of hunger-reducing hormones like GLP-1 (similar to drugs such as Wegovy and Ozempic) has b

GLP-1-boosting fibre approved as safe by European regulator, could be added to foods within a year

A novel form of fibre that stimulates the release of hunger-reducing hormones like GLP-1 (similar to drugs such as Wegovy and Ozempic) has b

Daily weight loss pill available in UK pharmacies from today

FDA Approves Foundayo (orforglipron): The First Oral GLP-1 Weight Loss Pill Without Fasting Requirements

The FDA approved Foundayo (orforglipron), a new once-daily oral GLP-1 weight loss pill by Eli Lilly, on April 1, 2026. Unlike other oral GLP

Sciwind has two Western partners for its obesity drug, but is open to more

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes